Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Athira Pharma, Inc.

Get SEC filing alerts via email and in your feed for Athira Pharma, Inc.

ATHA

Athira Pharma, Inc.

About Athira Pharma, Inc.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company developing orally available small molecule therapeutics that modulate the neurotrophic hepatocyte growth factor (HGF) system to restore neuronal health and slow neurodegeneration. Its lead candidate, ATH-1105, targets neurodegenerative diseases like ALS by promoting neuroprotection, reducing inflammation, and enhancing nerve function. Athira leverages proprietary drug discovery, third-party manufacturing, and aims to address unmet needs in central and peripheral nervous system disorders.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Athira Pharma, Inc.

1
1
Athira Pharma, Inc. LeonaBio Reports $32.9 Million Net Loss in Q1 2026, Driven by Increased R&D Expenses

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Athira Pharma, Inc. LeonaBio Reports Year-End Financial Results with Increased Net Loss and Business Update

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Athira Pharma, Inc. Athira Pharma Reports 77% Improvement in Quarterly Net Loss, Focuses on ALS Drug Development

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Athira Pharma, Inc. Athira Pharma Reports 74% Reduction in Quarterly Net Loss, Shifts Focus to ATH-1105

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Athira Pharma, Inc. Athira Pharma Reports $9.1 Million Net Loss in Q1 2025, Focuses on ATH-1105 Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Athira Pharma, Inc. Athira Pharma Reports Financial Challenges, Workforce Reduction, and Focus on Lead Drug Candidate

Via official filing (AI summary) | over 1 year ago | 0 comments